This is the story of how 3 Novartis colleagues took a career decision to improve health in lower income countries.
This series provides a glimpse into their experiences, challenges and the reward of seeing lives changed.
At Novartis, our people are exceptional. They do amazing work every day to reimagine medicine and improve the lives of patients all over the world. We want to build an inclusive environment that values these unique and curious minds, where everyone is inspired to innovate every day by this shared purpose to reimagine medicine.
That’s why we’re committed to building an inclusive and equitable workplace that looks beyond gender and empowers all of our associates to follow their dreams
Here are some of their stories:
Maryam is a cognitive robotics expert …
At Novartis, our people are exceptional. They do amazing work every day to reimagine medicine and improve the lives of patients all over the world. We want to build an inclusive environment that values these unique and curious minds, where everyone is inspired to innovate every day by this shared purpose to reimagine medicine.
That’s why we’re committed to building an inclusive and equitable workplace that looks beyond gender and empowers all of our associates to follow their dreams
Here are some of their stories:
Maryam is a cognitive robotics expert …
Wendi Yajnik has been building partnerships between academia and industry for the better part of her career. When it comes to emerging technologies, she’s seen it all – from cancer-fighting immunotherapies to gene editing tools to an approach to fat loss inspired by ice pops.
Now at Novartis, Yajnik heads Academic Partnerships and External Innovation for the Novartis Institutes for BioMedical Research (NIBR). Her team is responsible for bringing exciting new discoveries and technologies into Novartis from academia. Their efforts are helping drive NIBR’s strategy to build an …
- EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million.
- The PAMAfrica consortium brings together a global medicines company, a not-for-profit product development partnership and leading academic institutions in Africa and Europe. PAMAfrica aims to develop new medicines for both severe and uncomplicated malaria, designed to combat emerging artemisinin resistance.
- The projects will include development of the first new malaria …
Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long antitrust investigation into the U.S. generic drug industry. The Sandoz resolution relates to instances of misconduct at the company between 2013 and 2015 with regard to certain generic drugs sold in the United States. As part of the resolution, Sandoz has agreed to pay USD 195 million and will enter into a deferred prosecution agreement (DPA).
Sandoz is a global leader in …
March 11, 2020
Patient safety is at the heart of everything we do. Whenever adverse events are reported, we take them seriously and investigate them thoroughly.
As previously shared, our global safety organization is conducting a comprehensive review of a limited number of events reported as severe vision loss, retinal artery occlusion and/or vasculitis in patients treated with Beovu, including cases where patients had previously received other VEGF inhibitors.
To date, the data continue to support an overall favorable benefit-risk profile for …
Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long antitrust investigation into the U.S. generic drug industry. The Sandoz resolution relates to instances of misconduct at the company between 2013 and 2015 with regard to certain generic drugs sold in the United States. As part of the resolution, Sandoz has agreed to pay USD 195 million and will enter into a deferred prosecution agreement (DPA).
Sandoz is a global leader in generic …
- Shareholders approve 23rd consecutive dividend increase to CHF 2.95 (+4%) per share for 2019; representing a 3.5%1 yield and approximately 54% payout of free cash flow
- Shareholders confirm Dr. Joerg Reinhardt as Chairman of the Board of Directors as well as all other members who stood for re-election; Ms. Bridgette Heller and Mr. Simon Moroney elected to the Board of Directors
- Shareholders approve all other proposals of the Board of Directors, including the 2019 Compensation Report in an advisory …
Sandoz, a global generics leader and the #1 provider of off-patent antibiotic medicines worldwide, is making a public commitment to ensure stable pricing for a basket of essential medicines the company markets, which may help to treat coronavirus patients, amid growing concerns about the potential impact of the coronavirus outbreak on global supply chains.
Richard Saynor, Sandoz CEO, says: “I am very concerned about reports that prices for basic medicines such as painkillers and antibiotics are rising substantially as a result of a tightening supply situation for active …
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia